K
Karl-Ludwig Laugwitz
Researcher at Technische Universität München
Publications - 385
Citations - 16797
Karl-Ludwig Laugwitz is an academic researcher from Technische Universität München. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 58, co-authored 329 publications receiving 14350 citations. Previous affiliations of Karl-Ludwig Laugwitz include University of California, San Diego & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Postnatal isl1 + cardioblasts enter fully differentiated cardiomyocyte lineages
Karl-Ludwig Laugwitz,Alessandra Moretti,Jason T. Lam,Peter J. Gruber,Yinhong Chen,Sarah Woodard,Li Zhu Lin,Chen-Leng Cai,Min Min Lu,Michael Reth,Oleksandr Platoshyn,Jason X.-J. Yuan,Sylvia M. Evans,Kenneth B. Chien +13 more
TL;DR: Co-culture studies with neonatal myocytes indicate that isl1+ cells represent authentic, endogenous cardiac progenitors (cardioblasts) that display highly efficient conversion to a mature cardiac phenotype with stable expression of myocytic markers in the absence of cell fusion, intact Ca2+-cycling, and the generation of action potentials.
Journal ArticleDOI
Patient-specific induced pluripotent stem-cell models for long-QT syndrome.
Alessandra Moretti,Milena Bellin,Andrea Welling,Christian Jung,Jason T. Lam,Lorenz Bott-Flügel,Tatjana Dorn,Alexander Goedel,Christian Höhnke,Franz Hofmann,Melchior Seyfarth,Daniel Sinnecker,Albert Schömig,Karl-Ludwig Laugwitz +13 more
TL;DR: It was shown that myocytes derived from patients with long-QT syndrome type 1 had an increased susceptibility to catecholamine-induced tachyarrhythmia and that beta-blockade attenuated this phenotype.
Journal ArticleDOI
Multipotent Embryonic Isl1+ Progenitor Cells Lead to Cardiac, Smooth Muscle, and Endothelial Cell Diversification
Alessandra Moretti,Leslie Caron,Atsushi Nakano,Jason T. Lam,Jason T. Lam,Alexandra Bernshausen,Yinhong Chen,Yibing Qyang,Lei Bu,Mika Sasaki,Silvia Martin-Puig,Yunfu Sun,Sylvia M. Evans,Karl-Ludwig Laugwitz,Karl-Ludwig Laugwitz,Kenneth R. Chien +15 more
TL;DR: These studies document a developmental paradigm for cardiogenesis, where muscle and endothelial lineage diversification arises from a single cell-level decision of a multipotent isl1(+) cardiovascular progenitor cell (MICP).
Journal ArticleDOI
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Stefanie Schüpke,Franz-Josef Neumann,Maurizio Menichelli,Katharina Mayer,Isabell Bernlochner,Jochen Wöhrle,Gert Richardt,Christoph Liebetrau,Bernhard Witzenbichler,David Antoniucci,Ibrahim Akin,Lorenz Bott-Flügel,Marcus Fischer,Ulf Landmesser,Hugo A. Katus,Dirk Sibbing,Melchior Seyfarth,Marion Janisch,Duino Boncompagni,Raphaela Hilz,Wolfgang Rottbauer,Rainer Okrojek,Helge Möllmann,Willibald Hochholzer,Angela Migliorini,Salvatore Cassese,Pasquale Mollo,Erion Xhepa,Sebastian Kufner,Axel Strehle,Stefan Leggewie,Abdelhakim Allali,Gjin Ndrepepa,Helmut Schühlen,Dominick Angiolillo,Christian W. Hamm,Alexander Hapfelmeier,Ralph Tölg,Dietmar Trenk,Heribert Schunkert,Karl-Ludwig Laugwitz,Adnan Kastrati +41 more
TL;DR: Among patients who presented with acute coronary syndromes with or without ST-segment elevation, the incidence of death, myocardial infarction, or stroke was significantly lower among those who received prasugrel than amongThose who received ticagrelor, and the probability of major bleeding was not significantly different between the two groups.
Journal ArticleDOI
Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial.
Katrin Anette Fiedler,Michael Maeng,Julinda Mehilli,Stefanie Schulz-Schüpke,Robert A. Byrne,Dirk Sibbing,Petra Hoppmann,Simon Schneider,Massimiliano Fusaro,Ilka Ott,Steen Dalby Kristensen,Tareq Ibrahim,Steffen Massberg,Heribert Schunkert,Karl-Ludwig Laugwitz,Adnan Kastrati,Nikolaus Sarafoff +16 more
TL;DR: The results suggest that physicians should weigh the trade-off between ischemic and bleeding risk when choosing the shorter or longer duration of triple therapy.